I directed the full rebrand and digital transformation of Inozyme, partnering closely with their team to create a custom platform that supports both their rare-disease mission and their rapidly evolving scientific and stakeholder communications. Inozyme is a clinical-stage biotechnology company pioneering enzyme replacement therapies—like INZ-701—to address rare diseases tied to the PPi-Adenosine Pathway, such as ENPP1 and ABCC6 deficiencies

We built a bespoke content management system with Webflow, enabling the Inozyme team to easily publish scalable content—from clinical trial details and educational resources to community outreach for patients, families, and healthcare professionals

The goal was clarity and impact: make their science approachable and their mission clear, with a site that empowers both internal teams and the rare-disease community.

The result: a visually distinct, highly functional platform that supports Inozyme’s expanding outreach while honoring the seriousness and hope at the heart of their work.